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Abstract
Background: Aristolochiae Fructus (AF) and honey-fried Aristolochiae Fructus (HAF) have been used in China for a
long time as anti-tussive and expectorant drugs. Few clinical cases have been reported to be associated with the
toxicity of AF and HAF, although relatively high amounts of aristolochic acids (AAs) have been found in them. Our
previous experiments have verified from the chemical changes and from traditional toxicology that honey-processing
can significantly reduce the toxicity of AF. To further elucidate the detoxification mechanism of honey-processing,
comparative pharmacokinetics of AAs in AF and HAF are performed in this study.
Methods: An HPLC-MS/MS (high-performance liquid chromatography-tandem mass spectrometry) method was
developed and validated for the determination of AA I, AA II, AA C, AA D and 7-OH AA I in rat plasma. The
multi-component pharmacokinetics of AAs in AF and HAF extracts were investigated after the oral administration of
three doses to rats. The relative pharmacokinetic parameters were compared systematically.
Results: The five AAs shared a similar nonlinear PK (pharmacokinetic) process. They involve rapid absorption and
elimination, and they were fit into a two-compartmental open model. Some significant pharmacokinetic differences
were observed between the AF and HAF groups: the Cmax and AUC values of AA I and AA II in the AF groups were
much higher than those of the HAF groups.
Conclusions: Honey-frying technology can reduce the toxicity of AF by significantly decreasing the absorption of AA I
and AA II. The PK parameters obtained in this work could provide valuable references for the toxicity research
and clinical use of Aristolochiaceae herbs, including AF and HAF.
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Background
Aristolochiae Fructus (AF), the dry-ripe fruit of perennial
herb Aristolochia contorta BGE. or Aristolochia debilis
SIEB. et ZUCC., has been used in China for thousands
of years as an anti-tussive and expectorant drug with sig-
nificant curative effects [1]. The crude AF is bitter-cold
and can cause adverse reactions, such as nausea and
vomiting. Honey-Fried Aristolochiae Fructus (HAF), the
processed product of AF, has a stronger efficacy due to
its ability to moisten the lungs and relieve coughs. The
honey processing also improves the taste of AF, which
works to prevent vomiting; there is a saying that “frying
with honey makes the herbs sweet, mitigatory, and lung-
moistening” [2]. Consequently, HAF is more frequently
used than AF in the clinic.
Since the first aristolochic acid nephropathy (ANN)
case, aristolochic acids (AAs) have been proven to be
nephrotoxic [3, 4], carcinogenic [5, 6] and mutagenic [5,
7]. Therefore, most of the AAs-generating herbs and
herbal preparations have been banned in many countries,
including China. Recent reports [8–14] showed that the
AAs contents in some Aristolochiaceae (A.) herbs are in
the following order: A. manshuriensis>A. fangchi>A.
Ridix>A. Fructus>A. Herbra. Few clinical cases were re-
ported to be associated with the toxicity of AF and HAF,
and continue to be listed in Chinese Pharmacopoeia [1].
Although relatively high amountsof AAs exist in AF, only
moderate toxicity was observed during the acute and sub-
acute toxicity tests of its extract [15].
Drug processing is a traditional pharmaceutical technol-
ogy in traditional Chinese medicine, and it plays an im-
portant role in reducing the toxicity of traditional drugs.
Our previous experiments have found that the honey-
frying method can significantly reduce the contents of
AAs in AF [16]. However, even when the contents of AAs
were equivalent, the toxic effect of the HAF extract was
much weaker than that of the AF extract, and the results
suggested there should be another detoxification pathway
[15]. To understand the phenomenon of “low toxicity”
[15] and “a relatively high content of AAs” [8–14], it is ne-
cessary to investigate the pharmacokinetic or toxicokinetic
characteristics of AF and HAF.
Although the nephrotoxicity and mutagenic mechan-
ism of AAs are well studied, knowledge of the pharma-
cokinetic characteristics of AAs and related herbs is still
limited. Nowadays, the pharmacokinetic studies about
AAs focus mainly on AA I [17–19] and/or AA II
[20–25]; the other AAs are seldom involved. Very re-
cently, the preliminary pharmacokinetics of 4 AAs in
AF have been investigated by the CPE -HPLC (cloud
point extraction-high performance liquid chromatog-
raphy) method [26]. However, the method is tedious
and produces data with relatively poor sensitivity.
Therefore, in order to comprehensively investigate the
kinetics of multiple components in AF and HAF, a
more simple, fast, sensitive and effective analytical
method is necessary for the determination of AAs in
biological samples.
Advances in sample pretreatment and analytical tech-
niques have improved analysis time, sensitivity and effi-
ciency. A number of chromatography methods have
been reportedly used for the determination of AAs in
herbal plants [9–15] and biological samples [26–30].
Among these, high performance liquid chromatography-
tandem mass spectrometry (HPLC-MS/MS) has been
employed for the quantitative analysis of AA I [19] and
AA II [22, 29] in biological matrices. HPLC-MS/MS is
notable for its better specificity, sensitivity and speed.
In previous experiments, we found that honey-frying
technology could markedly reduce the contents of AAs
in AF and reduce its toxic effects and side effects. We
also discussed the detoxification mechanism of AF in
terms of two aspects: chemistry [16] and traditional toxi-
cology [15]. The primary goal of this work is to examine
the detoxification mechanism of AF from the kinetic
viewpoint using the honey-processing method. Firstly,
an HPLC-MS/MS method was developed and well vali-
dated for the determination of five AAs (AA I, AA II,
AA C, AA D and 7-OH AA I) in rat plasma. Secondly,
based on the proposed analytical method, a comparative
study was performed on the multi-component pharma-
cokinetics of AF and HAF extracts after the oral admin-
istration of three doses in rats.
Methods
Materials and reagents
A. Fructus was purchased from Haixing Chinese Herbal
Pieces Ltd (Bozhou, Anhui), and was authenticated as
the fruit of Aristolochia contorta Bunge by Professor
Wuliang Yang (Jiangxi University of Traditional Chinese
Medicine, JXUTCM). Voucher specimens are preserved
in the Herbarium of Pharmacognosy, School of Pharma-
ceutical Sciences, JXUTCM. Part of AF was processed
with honey to obtain HAF in our lab, according to the
Chinese Pharmacopoeia [1] and the literature [16].
Naproxen was purchased from the National Institute for
Food and Drug Control (Beijing, China). Five AAs, shown
in Fig. 1, were separated and purified in our laboratory and
their purities were no lower than 98% [13, 26]. Methanol
and acetonitrile were HPLC grade (Fairfield, OH, USA).
Purified water (Wahaha Group, Hangzhou, China) was
used throughout the experiments. All other chemical re-
agents were of analytical grade.
Animals
Male Sprague–Dawley (SD) rats (Certificate No. SCXK
(Hunan) 2011-001) weighting 200–220 g were purchased
from Hunan Silaike Jingda Experimental Animal Ltd
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(Changsha, China). The animals were kept in a controlled
breeding room with the following conditions: a
temperature of 22 ± 2 °C, a relative humidity of (65 ± 5)%,
and a 12 h light–dark cycle. The Experimental Animal
Ethic Committee of JXUTCM approved all animal proto-
cols. The animal experiments were carried out according
to the European Community guidelines for the use of ex-
perimental animals.
Preparation of stock solution, calibration standards and
quality control samples
The stock solutions of the mixed standards were pre-
pared in methanol with the concentrations of AA I
(9.15 μg/mL), AA II (8.00 μg/mL), AA C (7.45 μg/mL),
AA D (9.20 μg/mL) and 7-OH AA I (8.20 μg/mL).
Working standards were prepared freshly by diluting the
stock solution with methanol. Naproxen stock solution
(1.0 mg/mL) was dissolved in methanol, and was used as
an internal standard (IS). Using the stock solutions of
the mixed standard and internal standard, a series of
working standard solutions with gradient concentrations
of the derivatives and 1.0 μg/mL of internal standard
were prepared.
The relative calibration standards in plasma were pre-
pared by spiking 20 μl of the corresponding standard solu-
tions into 200 μl blank rat plasma. The quality control
(QC) samples used in the method validation were prepared
with the same procedures as the calibration standard.
Sample preparationof the extract and rat plasma
The dried AF (800 g) and HAF (928 g) were put in a
drug-decocting machine, respectively. The drugs were
extracted twice, the first time with 10 times the amount
of 95% ethanol for 2 h, and the second time with 8 times
the amount of ethanol for 1 h. Then the two decoctions
were merged and evaporated to dryness under vacuum.
An aliquot (100 μl) of rat plasma was spiked with
10.0 μL IS, and vortexed with 300 μL acetic ether for
10 s before the supernatant was transferred into centri-
fuge tube. The extraction was repeated with 200 μL
acetic ether. The combined organic layer was evaporated
to dryness under a gentle stream of nitrogen at RT. The
residue was resolved in 100 μL methanol and centri-
fuged at 15,800 × g for 10 min. The supernatant was
used for HPLC-MS/MS analysis.
Apparatus and HPLC-MS/MS conditions
The Agilent 1290 Infinity Binary LC system consists of
an autosampler, column oven, a degasser, and a binary
solvent manager (Agilent Technologies, CA, USA). The
Agilent 6410 triple-quadrupole mass spectrometer was
equipped with an electrospray ionization (ESI) source.
The HPLC-ESI-MS/MS system was controlled by Mas-
sHunter Workstation (Agilent Technologies, CA, USA).
Chromatographic separation was performed by an
Acquity C18 column (4.6 × 100 mm,3.5 μm) (Agilent Tech-
nologies, USA). The mobile phase was composed of water
(containing 10 mM ammonium formate and formic acid,
pH 3.0) (solvent A) and ACN (solvent B). The gradient
profile of B was: 0–10 min, 35–38%; 10–11 min, 38– 60%;
11–17 min, 60–35%B; 17–18 min, 35%. The flow rate was
kept at 0.5 mL/min. The column oven was set at 30 °C and
the injection volume was 10 μL.
The mass spectrometer was operated in the positive ion
electrospray mode with multiple reaction monitoring
(MRM). The optimal MS parameters were set at the fol-
lowing parameters: a desolvation gas temperature of 450 °
C, desolvation gas flow of 10 L/min, a nebulizer gas of
40 psi and a capillary voltage of 4000 V. The mass spec-
trometry conditions of AA I, AA II, AA C, AA D, 7-OH
AA I and IS are summarized in Additional file 1: Table S1.
Method validation
This method was validated as per the current ICH guide-
lines. To assess the linearity ranges, a series of the mixed
standard solutions (seven concentration levels) were pre-
pared in triplicate. Each calibration curve (y = ax + b) was
established by plotting the peak area ratio of analyte
to IS (y) against the concentrations (x) of the calibra-
tion solution with a least square linear regression
analysis. The correlation coefficient (r2) of the calibra-
tion curve should be >0.990 to satisfy linearity re-
quirements. The limit of detection (LOD) and limit of
quantification (LOQ) were determined when the peak
height was three times and ten times the background
noise, respectively.
The intra- and inter-day precisions and accuracies
were calculated by an analysis of variance based on the
replicate analysis of QC samples, and the work was ac-
companied by a standard calibration curve on each ana-
lytical run. The precision and accuracy were required to
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Fig. 1 Structures of five AAs (AA I, AA II, AA C, AA D and 7-OH AA I)
and naproxen (internal standard, IS)
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the lower limit of quantification (LLOQ) and within
±15% (RSD%) for other concentrations. Precisions were
evaluated under the optimal conditions six times within
the same day for intra-day variance and six different
days for inter-day variance. The accuracy was deter-
mined by calculating the percentage deviation of the ob-
served concentrations from the spiked concentrations
and expressed as a relative error (R.E.%). The recovery
tests were studied by spiking the known content of the
mixed standard into the blank plasma and calculated as
follows: (mean measured concentration)/(spiked concen-
tration) × 100%.
The extraction recoveries of five analytes were assessed
by comparing the mean peak areas of QC samples free of
IS (A) with those of the spike-after-extraction samples (B)
at the same concentrations (n = 6). Likewise, the matrix ef-
fects were tested by comparing the peak areas of B with
those of the corresponding concentration of mixed stand-
ard solution (dissolved in methanol) (C). There was no
matrix effect if the ratio was between 85~115%.
The QC samples were assayed under several different
conditions to evaluate the stability of AAs in rat plasma.
The freeze-thaw stability of the analyte was determined
over three freeze-thaw cycles. In each freeze-thaw cycle,
the samples were frozen and stored at –20 °C for 24 h,
then thawed at room temperature. To evaluate the long-
term stability of AAs, the plasma samples were stored at
–20 °C for 14 days. For the short-term stability, fresh
plasma samples were kept at room temperature for 24 h
before the sample preparation. After keeping the sam-
ples at room temperature for 24 h, post-preparation sta-
bility was tested. Stability was evaluated by comparing
the mean concentration of the stored samples with the
mean concentration of those prepared freshly. The sta-
bility data were acceptable when the bias was within
±15% of the actual value.
Pharmacokinetic experiment
The rats were randomly divided into 6 groups (low, mid-
dle and high doses of AF and HAF; n = 6). After a week
of acclimation, the animals were fasted for 12 h with free
access to water. Then, AF and HAF extracts were ad-
ministered to the rats. The extracts were suspended in
0.5% CMC–Na solution, and the oral doses (according
to AA I in the extracts) were 3.0 mg/kg, 8.0 mg/kg and
15.0 mg/kg, respectively.
Blood samples were collected from the ocular vein
using dried heparinized tubes at 0, 0.083, 0.17, 0.33,
0.50, 0.67, 0.83, 1, 2, 4, 6, 8, 10, 12 and 24 h from the
start. The animals received fluid replacement (sterile iso-
tonic saline) after every two samplings since the fifth
collecting. The samples were then immediately centri-
fuged at 3100 × g for 10 min. The plasma obtained was
frozen and stored at –20 °C until analysis.
All statistical analyses were performed using the SPSS
11.0 software (Chicago, USA). P values <0.05 were con-
sidered statistically significant. Pharmacokinetic analysis
was performed using the proprietary DAS 3.0 software




Some sample preparation methods have been reported
for the AAs in biosamples, including protein precipitation
[25, 29], liquid-liquid extraction (LLE) [19, 24, 27, 28],
solid-phase extraction [31, 32], liquid-phase microextrac-
tion [33] and cloud-point extraction [26]. In this work, the
deproteinized methods (with methanol or acetonitrile)
and the liquid–liquid extraction (with ethyl acetate and
chloroform) were investigated, and the extraction recover-
ies and matrix effects were selected as the evaluation in-
dexes. No significant differences were observed between
the extraction recoveries of these methods. However, the
matrix effect of the LLE with ethyl acetate was lower than
that of protein precipitation. Ethyl acetate was conse-
quently selected as the extraction solvent due to its lesser
toxicity and good volatility. As shown in Additional file 2:
Table S2, the current method was provided with suitable
extraction recoveries and matrix effects.
Selection of internal standard
In our early experiments, indomethacin was used once as
an internal standard to quantify the AAs in biosamples.
Gu et al. [29] reported the feasibility of naproxen as IS
when analyzing AA I and AA II in the rat plasmas. In this
work, the retention behavior and MS characteristics of
indomethacin and naproxen were investigated. Indometh-
acin has a weaker polarity and a longer retention time
than the AAs do. However, the retention time of naproxen
is between that of AA D and AA I, with a suitable MS re-
sponse. In order to shorten the analysis time, naproxen
was selected as the internal standard substance.
Optimum chromatography and mass spectrometry
conditions
Aristolochic acids are a mixture of structurally related
nitrophenanthrene carboxylic acids with a weak polarity
and low ionization efficiency [12, 34]. These compounds
have very similar molecular structures; 7-OH AA I and
AA D are isomers and difficult to separate in a short
time. To get optimum chromatography and mass spec-
trometry conditions, various influencing factors such as
the chromatographic column, the mobile phase, and MS
parameters were optimized.
To obtain a good separation, several analytical col-
umns, including Acquity C18 (4.6 × 100 mm, 3.5 μm)
(Agilent Technologies), YMC-Tiart C18 (3.0 × 150 mm,















Fig. 2 Typical MRM chromatograms of blank plasma (a), blank plasma spiked AAs and IS (b), and plasma samples at 30 min after administration (c)
Table 1 Linear parameters of five AAs in rat plasma
AAs Linear equation r2 Linear range (ng/mL) LOD (ng/mL) LLOQ (ng/mL)
AA I Y1 = 0.0227X1-0.64 0.9998 1.46~9150 0.3 0.73
AA II Y2 = 0.0081X2-0.1013 0.9999 3.20~8000 1.2 3.20
AA C Y3 = 0.0021X3-0.0126 0.9986 74.5~7450 23.8 74.5
AA D Y4 = 0.0094X4-0.0522 0.9996 14.7~9200 3.7 14.7
7-OH AA I Y5 = 0.0074X5-0.0615 0.9997 32.8~8200 13.1 32.8
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3.0 μm) (YMC Co. LTD, Tokyo, Japan) and Welch ultim-
ate® UHPLC XB-C8 (2.1 × 100 mm, 2.1 μm) (Welch Mate-
rials, Shanghai, China) were investigated. Agilent columns
were found to have better separation and lower column
pressure and therefore were used in subsequent experi-
ments. Based on previous work [12, 22, 29, 34], chromato-
graphic conditions such as the constituents and the
gradient profiles of the mobile phase were further im-
proved to adapt the separation and detection of AAs in
rat plasma. In addition, the optimum mobile phase was
water (containing 10 mM ammonium formate and formic
acid, pH 3.0) and acetonitrile.
In the experiment, the studied AAs were found to eas-
ily form ammonia adducts [M+NH4]
+ (Additional file 3:
Figure S1). Thus, the precursor ions were set at m/z 359
[AA I+NH4]
+, m/z 329 [AA II+ NH4]
+, m/z 345 [AA C
+NH4]
+, m/z 375 [AA D+NH4]
+ and m/z 375 [7-OH AA
I+NH4]
+ to provide the best detection sensitivity. The
most intense precursor–product transitions were se-
lected as the quantification transitions in the multiple
reaction monitoring (MRM) mode. The product ions
with higher abundances were selected according to
the fragmentation of the mass spectra of the above
precursor ions, and the fragment ions at m/z 298
[AA I+H-CO2]
+, m/z 268 [AA II+H-CO2]
+, m/z 282
[AA C+H-NO2]
+, m/z 312 [AA D+H-NO2]
+ and m/z
314 [7-OH AA I+H-CO2]
+ were therefore selected as
the product ions. It can be seen from Fig. 2, that no
interference peaks in the chromatograms from endo-
genic metabolites of rat blood were observed. Further-
more, a good separation of AAs was obtained under
optimal conditions. The results indicate the proposed
method has good specificity.
Method validation
Typical chromatograms of blank, spiked plasma and
plasma samples are shown in Fig. 2. The developed
method results in 6 single sharp peaks at the retention
Table 2 Precision, accuracy and recovery of AAs in rat







AA I 1.83 0.7 1.4 12.2 112.1
457.5 8.5 13.5 5.9 105.9
1830 14.1 13.2 2.1 102.1
AA II 8.00 2.9 3.2 −2.5 97.6
400 10.9 7.9 8.2 108.1
3200 13.1 4.6 −3.7 96.4
AA C 186.3 10.9 4.7 −8.4 91.7
372.5 10.9 13.6 4.2 104.2
2980 6.2 7.7 −6.2 93.9
AA D 36.8 11.9 15.3 −12.5 87.6
460 12.3 8.8 13.3 113.4
3680 11.1 13.6 −9.2 90.8
7-OH AA I 82.0 11.3 13.3 3.0 103.0
410 13.8 7.2 −2.8 97.2
3280 6.2 7.3 7.7 107.7











AA I 1.83 1.1 0.28 0.58 0.65
457.5 10.3 6.9 8.7 2.0
1830 12.9 7.6 6.5 4.5
AA II 8.00 1.3 1.2 5.0 4.4
400 10.2 8.2 5.5 3.6
3200 14.3 7.3 9.3 6.5
AA C 186.3 5.8 8.3 14.0 9.2
372.5 7.3 9.9 12.6 8.5
2980 12.9 12.0 13.0 7.0
AA D 36.8 4.8 5.2 5.0 4.5
460 8.4 2.5 11.7 3.1
3680 14.3 12.7 8.6 2.8
7-OH AA I 82.0 6.2 2.0 7.1 5.1
410 12.3 6.4 11.8 4.2
3280 13.4 11.1 9.1 6.7
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Fig. 3 Mean plasma concentration-time profile of five AAs in rats after oral administration of AF & HAF extracts at three doses (n = 6)
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time of 6.9, 8.6, 9.2, 14.8, 15.2 and 16.2 min. No interfer-
ence was found between endogenous compounds or xe-
nobiotics and AAs.
The linearity parameters of five AAs in rat plasma are
summarized in Table 1. Within the investigated linear
range, good linearity data was obtained with correlation
coefficients >0.998. The results indicate that the
method has suitable sensitivity with LODs downward
of 0.3 ng/mL and LLOQs downward of 0.73 ng/mL.
The accuracy and precision results are shown in Table 2.
The analytical precisions were less than 15%, the relative
errors were within −12.5~13.3%, and the recoveries were
within 87.6~113.4%. These data indicate that the HPLC-
MS/MS method provides suitable, reproducible, accurate,
and reliable data and can be used as an analytical tool of
AAs in rat plasma.
The stability data under different experimental condi-
tions are summarized in Table 3. The detection variabil-
ities expressed as RSDs (%) were less than 14.3%, which
suggested that rat plasma samples containing AAs were
stable under routine laboratory conditions and no add-
itional procedures were necessary to stabilize the sample
for pharmacokinetic studies.
Contents of AAs in extract and dose of intragastric
administration
The dry extract yield of AF and HAF were 2.87 and
17.04%, respectively. The five main aristolochic acids in
the extracts of AF and HAF were determined by an im-
proved HPLC method [26], and the content results are
summarized in the Additional file 4: Table S3. The re-
sults showed that the contents of AAs in the AF extract
were much higher than that in the HAF extract. Even
after taking into consideration the extract, the content
of AAs in HAF decreased significantly compared to the
content in AF, which indicated that the honey-frying pro-
cessing technology reduces the content of AAs in AF [15].
In previous pharmacokinetic studies of AA I and/or AA
II, the dose range was about 5~15 mg/kg [19–22, 24]. In
this study, three doses were used, equivalent to AA I con-
tent in the extract: low dose (3.0 mg/kg), middle dose
(8.0 mg/kg) and high dose (15.0 mg/kg). Then, the relative
AF and HAF extracts were weighed out to prepare the
drug solutions for the rats.
Pharmacokinetic study of the five AAs
After the oral administration of AF and HAF extracts,
rat plasma samples were prepared and analyzed as de-
scribed above. The typical chromatograms were shown
in Fig. 2. Five main AAs can be detected in rat blood
with the proposed HPLC-MS/MS method. The mean
plasma concentration–time profiles of AAs after the oral
administration of AF and HAF extracts are shown in
Fig. 3. The mean pharmacokinetic parameters of five
AAs in AF and HAF are summarized in Tables 4, 5 and
Additional files 5, 6, 7: Tables S4-S6. The maximum con-
centration (Cmax) was the experimentally-observed value.
The other pharmacokinetic parameters of the five ana-
lytes were fitted by DAS 3.0 software.
The five AAs shared some similar pharmacokinetic pa-
rameters, which may be due to the similarity of their
structures. They were absorbed quickly and their Tmax
values were in the range of 0.43~1.83 h (see Fig. 3,
Tables 4, 5 and Additional files 5, 6, 7: Tables S4-S6).
Similar metabolisms were observed for the studied AAs
and relative metabolites, including aristolactams and
DNA adducts, were detected in the rat urine, feces and
kidney tissues according to the improved analytical
methods [28, 32, 35]. As can be seen from Fig. 3, they
were also excreted rapidly. The physiological disposition
conformed to a two-compartmental open model of the
five AAs in rats fitted by the DAS 3.0 software. No good
linear relationships were observed between Cmax and
AUC for the doses. These parameters suggest that the
pharmacokinetics of AAs in rats are nonlinear.
There were also some differences between the parame-
ters of various AAs. The ratios (AUC(0-∞)/dose) of AA I
and AA II were higher than those of the other AAs, and
thet1/2zvalues were in the following order from large to
small: AA I, AA II, 7-OH AA I, AA D and AA C. The
results show that the absorption rates of AA I and AA II
were higher than those of the others, and more
Table 4 PK parameters of AA I in rats after oral administration of AF and HAF (mean ± SD, n = 6)
Parameter Unit Low-dose Mid-dose High-dose
AF HAF AF HAF AF HAF
Dose mg/kg 3.0 3.0 8.0 8.0 15.0 15.0
Cmax μg/L 1704.0 ± 570.8 1072.3 ± 223.1* 3823.8 ± 450.3 2002.5 ± 312.8* 5891.3 ± 425.5 3474.3 ± 352.3*
Tmax h 0.50 ± 0.09 0.39 ± 0.08 0.56 ± 0.09 0.42 ± 0.08 0.69 ± 0.10 0.47 ± 0.08
t1/2z h 3.50 ± 0.50 3.22 ± 0.46 5.58 ± 0.65 4.72 ± 0.52 5.46 ± 0.53 5.32 ± 0.54
AUC(0-∞) μg/L · h 6080.4 ± 1263.2 5227.0 ± 895.6* 12770.7 ± 1857.5 8985.3 ± 1784.9* 26844.6 ± 3264.7 11782.2 ± 1769.2*
Vz/F L/kg 2.85 ± 0.15 2.75 ± 0.24 5.40 ± 0.48 4.58 ± 0.37 7.13 ± 0.57 5.53 ± 0.52
CLz/F L/h/kg 0.57 ± 0.06 0.59 ± 0.08 0.65 ± 0.09 0.68 ± 0.07 0.87 ± 0.12 0.72 ± 0.08
*P < 0.05 compared with AF group
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clearance time was needed. These differences can par-
tially explain why AA I and AA II are the most toxic
compounds of the total AAs from a pharmacokinetic
viewpoint.
Pharmacokinetics comparisons between AF and HAF
Some significant pharmacokinetic differences were ob-
served between the AF and HAF groups (see Fig. 3,
Tables 4, 5 and Additional files 5, 6, 7: Tables S4-S6).
The parameters, such as Cmax and AUC (including
AUC (0-t) and AUC(0-∞)), of AA I and AA II in the
AF groups were are much higher than those of the
HAF groups (Tables 4 and 5), which indicates that
the absorption rates of AA I and AA II by rats de-
creased significantly in HAF groups (p < 0.01). These
results imply that honey-frying could reduce the ab-
sorbability of AA I and AA II, thereby alleviating the
toxic effects caused by herbal plants containing AAs.
The other pharmacokinetics differences are not so
significant. Firstly, relatively small differences were
observed for the other PK parameters of AA I and
AA II between the AF and HAF groups, such as Vz
and CLz. Secondly, no very significant differences were ob-
served for the parameters of the other three AAs (AA C,
AA D and 7-OH AA I) between the AF and HAF groups
(Additional files 5, 6, 7: Tables S4-S6). Thirdly, the similar
metabolites of the AAs are detected in the rat urine, feces
and kidney tissues of AF and HAF groups, which indicate
AAs in AF and HAF groups experienced a similar meta-
bolic pathway.
In summary, honey-frying affected the physiological
disposition of AAs in rats, especially the absorption of
AA I and AA II. But how the physiological action was
changed by honey-frying requires further investigation.
Berenbaum’s group once reported that honey constitu-
ents can up-regulate detoxification and immunity genes
[36], but the regulation should be a relatively long
process and might not occur in the current PK experi-
ments. According to the previous experiments [15, 16]
and the current results, we can now deduce the detoxifi-
cation mechanism of AF using honey-processing. It was
found that the significant content decrease of AAs [16];
and the remarkable absorption decreases of AA I and
AA II.
Conclusions
Honey-frying technology can reduce the toxicity of
AF by decreasing the absorption of AA I and AA II,
and by reducing the content of AAs. The results have
validated the scientific connotation of the honey-
frying technology of AF. HAF, therefore, is recom-
mended in clinical use instead of its crude drugs (AF)
because of its increased safety. The PK parameters
obtained in this work could provide valuable refer-
ences for toxicity research and the clinical use of
Aristolochiaceae herbs, including AF and HAF.
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